Statement: the primary trial and the secondary trial recorded none of the same types of adverse events
Primary_evidence: Adverse Events 1:   Total: 27/50 (54.00%)   Febrile neutropenia * 4/50 (8.00%)   Anaemia * 1/50 (2.00%)   Neutropenia * 1/50 (2.00%)   Cardiac failure * 1/50 (2.00%)   Diarrhoea * 1/50 (2.00%)   Gastritis * 1/50 (2.00%)   Nausea * 1/50 (2.00%)   Oesophagitis * 1/50 (2.00%)   Pyrexia * 7/50 (14.00%)   Mucosal inflammation * 1/50 (2.00%)   Drug hypersensitivity * 1/50 (2.00%)   Cellulitis * 2/50 (4.00%)
Secondary_evidence: Adverse Events 1:   Total: 158/482 (32.78%)   Anaemia 7/482 (1.45%)   Disseminated intravascular coagulation 1/482 (0.21%)   Lymphadenopathy 0/482 (0.00%)   Neutropenia 0/482 (0.00%)   Thrombocytopenia 2/482 (0.41%)   Anaemia 28/482 (1.66%)   Disseminated intravascular coagulation 21/482 (0.21%)   Febrile neutropenia 21/482 (0.21%)   Lymphadenopathy 20/482 (0.00%)   Neutropenia 20/482 (0.00%) Adverse Events 2:   Total: 37/238 (15.55%)   Anaemia 2/238 (0.84%)   Disseminated intravascular coagulation 0/238 (0.00%)   Lymphadenopathy 1/238 (0.42%)   Neutropenia 1/238 (0.42%)   Thrombocytopenia 0/238 (0.00%)   Anaemia 22/238 (0.84%)   Disseminated intravascular coagulation 20/238 (0.00%)   Febrile neutropenia 21/238 (0.42%)   Lymphadenopathy 21/238 (0.42%)   Neutropenia 21/238 (0.42%)